Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Continues to make progress on all front

Auriga reiterates a 'Buy' on The Medicines Company (NASDAQ: MDCO) price target of $65.00.

Analyst, Difei Yang, said, "Q1 financials beat street consensus on revenue and GAAP EPS. Angiox sales growth in Europe is stronger than expected. R&D activities on track to give two valuation driving events -- top line results from SOLO I during Q4 and interim results on Cangrelor during Q3 of this year. AZ-deal brings $15 million co-promotion fee which covers more than half of MDCO's sales force costs."

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $21.52 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
• UBS Reiterates Buy Rating on HF Sinclair (DINO)